Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 11, Number 8—August 2005

Research

Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use

Conan MacDougall*, Spencer E. Harpe*, J. Patrick Powell*, Christopher K. Johnson†, Michael B. Edmond*, and Ron E. Polk*Comments to Author 
Author affiliations: *Virginia Commonwealth University, Richmond, Virginia, USA; †Idaho State University, Boise, Idaho, USA

Main Article

Figure 1

Fluoroquinolone use and resistance over study period. FQ, fluoroquinolone; Levo, levofloxacin; Cipro, ciprofloxacin; Moxi, moxifloxacin; Gati, gatifloxacin; DDD/1,000PD, defined daily doses/1,000 patient-days; FQ-R PSA, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.

Figure 1. . Fluoroquinolone use and resistance over study period. FQ, fluoroquinolone; Levo, levofloxacin; Cipro, ciprofloxacin; Moxi, moxifloxacin; Gati, gatifloxacin; DDD/1,000PD, defined daily doses/1,000 patient-days; FQ-R PSA, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.

Main Article

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO